Fera Pharmaceuticals has announced that it has acquired all rights, title, and interest to seven prescription sterile anti-infective ophthalmic Abbreviated New Drug Applications (ANDAs) marketed by Fougera. The products include Bacitracin; Bacitracin Zinc and Polymixin B Sulfate; Gentamicin Sulfate, Neomycin and Polymyxin B Sulfates and Bacitracin Zinc; Neomycin and Polymyxin B Sulfates and Dexamethasone; Neomycin and Polymyxin B Sulfates, Bacitracin Zinc and Hydrocortisone Acetate, as well Erythromycin Ophthalmic Ointments USP.

Bacitracin ophthalmic ointment is expected to be made available by Fera in September 2009.  At launch, Fera will be distributing limited inventories of Fougera labeled Bacitracin ophthalmic ointment while initiating technical transfers and obtaining required regulatory approvals for the rest of the line.  It is anticipated the Fera labeled product will be available early 2010.

For more information call (516) 277-1450 or visit www.ferapharma.com.